logo
  Join        Login             Stock Quote

Medtronic (MDT): FDA Oks New Sizes Of Resolute Integrity Drug-Eluting Stent

 February 25, 2013 11:06 AM
 


(By Balachander) Medtronic Inc. (NYSE: MDT) said it has received approval from the U.S. health regulators for longer lengths of the company's  Resolute Integrity drug-eluting stent with an indication for patients with diabetes.

The new sizes of the Resolute Integrity stent enable the treatment of long coronary lesions, which are generally considered to span more than 27mm, the Minneapolis-based medical technology said.

Medtronic added that the new sizes of the Resolute Integrity drug-eluting stent address both challenges in a single device. They have the potential to reduce procedure time and cost for clinicians and hospitals, as well as vessel trauma and contrast exposure for patients.

[Related -Medtronic, Inc. (MDT): Turning The Beat Around?]

The U.S. Food and Drug Administration (FDA) has cleared the 34mm and 38mm lengths of the company's Resolute Integrity drug-eluting stent in diameters of 3.0mm, 3.5mm and 4.0mm.

The company said the 34mm and 38mm lengths of the Resolute Integrity stent are uniquely indicated for treating the coronary artery disease of patients with diabetes, who commonly present with long lesions.

The FDA approval is based on an analysis that included data on 222 patients who received a 38mm Resolute stent for the treatment of coronary lesions of no greater than 35mm in length.

The stock, which has been trading in the 52-week range of $35.67 to $47.40, inched up 0.36 percent to trade at $44.88 on Monday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageThe Chip Maker Short Sellers Should Be Watching

Investing in semiconductor stocks is always tricky. Industry cycles can lead to bumps in the road for the read on...

article imageChicago Fed: US Economic Growth Slowed In October

The pace of US growth slowed more than expected in October, according to this morning’s update of the read on...

article imageHoliday Fever Takes Hold Of Stock Investors, But A Pullback Is Needed

With warmer weather arriving to melt the early snowfall across much of the country, investors seem to be read on...

article imageIs 0% Growth For 90% A Successful Economic Model?

Via Greg Mankiw I read the review of Piketty's book by Deirdre McCloskey. The review reminds me of the read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.